GSK Says Teva's Skinny-Label Row Is 'No Threat' To Generics

By Dani Kass (August 19, 2022, 9:45 PM EDT) -- Teva Pharmaceuticals' "doomsday scenario" that upholding a $235 million infringement verdict against it would destroy a practice that gets generic drugs on the market sooner doesn't hold up when the facts of the case are reviewed, GlaxoSmithKline told the U.S. Supreme Court on Friday....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!